



Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13

August 29, 2017

-- Presentation to be webcast on www.exelixis.com --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 29, 2017-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 11-13 in New York, NY. The Exelixis presentation is scheduled for 11:40 AM EDT / 8:40 AM PDT on Wednesday, September 13, 2017.

The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETRYX[®] tablets approved for previously treated advanced renal cell carcinoma and COMETRIQ[®] capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC[®], is a formulation of cobimetinib, a reversible inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information about Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170829006082/en/>

Source: Exelixis, Inc.

Exelixis, Inc.
Susan Hubbard, 650-837-8194
EVP, Public Affairs & Investor Relations
shubbard@exelixis.com

or

For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com